Different perspectives and educational resources
Educational resources about unmet needs in later lines of CML
Expert Perspectives
Additional Resources
Unmet need
- Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168-2171.
- Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497-5500.
Off-target activities
- Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
- Karaman MW, Herrgard H, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
- Huang D, Zhou T, Lafleur K, Nevado C, et al. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics. 2010;26(2):198-204.
Mechanism of action
- Fallacara AL, Tintori C, Radi M, et al. Insight into the allosteric inhibition of Abl kinase. J Chem Inf Model. 2014;54(5):1325-1338.
CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.
